Let's review the two obesity treatments, Wegovy and ... placebo group. GLP-1 is being studied for stunting the worsening of Parkinson's Disease. The daily candlestick chart on LLY indicates ...

The FDA removed Lilly’s GLP-1 medications, Mounjaro and Zepbound, from its shortage list in December 2024, followed by Novo Nordisk’s Ozempic and Wegovy in February 2025. This decision was ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current market consensus, flagging "sluggish" trends for Ozempic and Wegovy. Investors and analysts also see cause for concern ...